Category: What’s News Asia

Sejak kemitraan dimulai pada September 2025, lebih dari 1.000 kotak makanan telah didistribusikan kepada warga lansia di seluruh komunitas lokal. Setiap paket berisi bahan makanan pokok seperti beras, kacang hijau, gula, susu, madu, dan telur; membantu memastikan bahwa kebutuhan nutrisi dasar terpenuhi dengan bermartabat dan penuh perhatian.

Selain bantuan makanan, inisiatif ini juga mencakup pemeriksaan mata gratis dan penyediaan kacamata untuk individu lansia yang membutuhkan dukungan penglihatan, memperkuat fokus yang lebih luas pada kesejahteraan daripada bantuan sekali waktu.

Distribusi 12 Februari: Memperluas Dukungan Selama Ramadan

• Pada tanggal 12 Februari, putaran bantuan terbaru menjangkau ratusan anggota komunitas lansia. Distribusi tersebut meliputi:
• 300 kotak makanan berisi bahan pokok rumah tangga
• 300 perlengkapan kebersihan berisi pasta gigi, sikat gigi, sabun, pembersih lantai, dan kebutuhan sehari-hari lainnya
• 300 kotak makan siang yang baru disiapkan termasuk nasi dengan ayam, sayuran goreng, tahu atau perkedel jagung, biskuit, buah (pisang atau jeruk), dan air mineral

Inisiatif ini menjadi lebih bermakna berkat keterlibatan sukarelawan lokal dari Komunitas Olymptrade Indonesia. Partisipasi mereka membantu mengubah distribusi dari upaya logistik menjadi pertukaran yang personal dan penuh empati.

Ramadan secara luas diakui sebagai waktu untuk bermurah hati, merenung, dan berbagi tanggung jawab. Dengan mendukung warga lanjut usia selama periode ini, platform perdagangan tersebut berupaya memperkuat nilai-nilai kebaikan dan kepedulian kolektif yang sangat berakar dalam masyarakat Indonesia.

Komitmen Berkelanjutan kepada Komunitas

Kemitraan dengan YUM Community Center mencerminkan komitmen berkelanjutan, bukan upaya sekali waktu. Sejak September 2025, kolaborasi yang konsisten telah memberikan lebih dari 1.000 kotak makanan, menyediakan dukungan medis, dan memperkuat ikatan lokal melalui keterlibatan langsung yang berkelanjutan.

Yang paling menonjol bukanlah hanya skala dukungannya, tetapi juga keberlanjutannya. Para sukarelawan kembali, hubungan semakin erat, dan warga lanjut usia tahu bahwa mereka tidak dilupakan setelah berita utama mereda. Seiring berjalannya Ramadan, fokusnya tetap sederhana: memberikan bantuan praktis, hadir secara konsisten, dan memastikan bahwa perawatan berlanjut melampaui satu hari distribusi.

Hashtag: #Olymptrade

The issuer is solely responsible for the content of this announcement.

Since the partnership began in September 2025, more than 1,000 food boxes have been distributed to elderly residents across local communities. Each package included staple items such as rice, mung beans, sugar, milk, honey, and eggs; helping ensure that basic nutritional needs were met with dignity and care.

Beyond food assistance, the initiative has also included free eye checkups and the provision of eyeglasses for elderly individuals requiring vision support, reinforcing a broader focus on well-being rather than one-time aid.

February 12 Distribution: Expanding Support During Ramadan

On February 12, the latest round of support reached hundreds of elderly community members. The distribution included:

• 300 food boxes containing essential household staples
• 300 hygiene kits with toothpaste, toothbrushes, soap, floor cleaner, and other daily necessities
• 300 freshly prepared lunch boxes including rice with chicken, fried vegetables, tofu or corn fritters, crackers, fruit (bananas or oranges), and mineral water

The initiative was made even more meaningful through the involvement of local volunteers from the Olymptrade Indonesia community. Their participation helped transform the distribution from a logistical effort into a personal and compassionate exchange.

Ramadan is widely recognized as a time of generosity, reflection, and shared responsibility. By supporting elderly citizens during this period, the trading platform sought to reinforce the values of kindness and collective care that resonate deeply within Indonesian communities.

A Continued Commitment to the Community

The partnership with YUM Community Center reflects an ongoing commitment rather than a one-time effort. Since September 2025, consistent collaboration has delivered more than 1,000 food boxes, provided medical support, and strengthened local ties through steady, hands-on involvement.

What stands out most is not only the scale of the support, but its continuity. Volunteers return, relationships deepen, and elderly residents know they are not forgotten once the headlines fade. As Ramadan continues, the focus remains simple: provide practical help, show up consistently, and ensure that care extends beyond a single distribution day.

Hashtag: #Olymptrade

The issuer is solely responsible for the content of this announcement.

透過迪士尼電影《無敵破壞王》雲妮露的想像，整座園區由春季直至初夏時節化為美味誘人的歡樂甜點世界。不僅米奇等迪士尼明星將在此暢遊，遊客亦可擁有美妙的遊園體驗。

活動期間，遊行表演「繽紛甜點時刻！」於遊行路徑熱鬧登場。屆時，遊行花車將紛紛展現由繽紛甜點打造而成的可愛度假區景象，雲妮露、米奇等迪士尼明星也將同時亮相，呈獻滿載歡樂氣氛的甜點時光。

自3月9日起，特別餐飲、部分特別商品、園區裝飾將於特別活動開始之前搶先登場。今年，園方首度推出可自由搭配的好友樂力四射百匯。遊客於餐飲設施享用百匯時，歡迎依喜好選擇淋醬與配料。商店亦銷售同名的甜點套組，可供遊客自行挑選糖果餅乾，放入隨身包或設計靈感來自百匯的百匯杯。豐富多樣的特別商品、特別餐飲相互交織出多彩甜美的夢幻世界，引領遊客沉浸其中。此外，園區入口附近的米奇花壇將以糖果主題打造，世界市集、灰姑娘城堡前方的圓環、部分餐飲設施亦布置外觀彷若甜甜圈、棒棒糖等甜點風格的裝飾，滿載甜蜜可愛氛圍。

除上述內容之外，迪士尼飯店也將推出精心烹調的特別餐飲，打造難以忘懷的味蕾體驗。迪士尼度假區線亦同步銷售獨家設計的周遊券，令東京迪士尼度假區洋溢雲妮露想像的甜蜜世界。

歡迎與親朋好友及心愛伴侶一同暢遊春季爽朗晴空下的東京迪士尼度假區，在美味誘人的甜點世界度過無與倫比的歡樂時光。

［一般諮詢］東京迪士尼度假區官方網站
https://www.tokyodisneyresort.jp/tc/topics/event/vanellopessweetpopworld.html

※圖片皆僅供參考。© Disney

Hashtag: #東京迪士尼樂園

The issuer is solely responsible for the content of this announcement.

SINGAPORE – Media OutReach Newswire – 24 February 2026 – In the wake of Budget 2026 and Prime Minister Lawrence Wong’s announcement of a National AI Council to accelerate mission-driven artificial intelligence deployment, EtonHouse International Education Group has collaborated with OpenAI to roll out ChatGPT Edu across its global education network, establishing a secure, enterprise-grade AI workspace designed to strengthen governance, operational excellence and institutional capability.

The implementation spans the Group’s schools and education brands, including EBridge Pre-School, an Anchor Operator, extending AI integration beyond classroom experimentation into enterprise-wide infrastructure supporting operations, marketing and admissions, finance, human resources, school administration and technology development.

While education was not named among the initial priority sectors identified under Singapore’s national AI strategy, EtonHouse views schools as foundational to building long-term AI capability and literacy across society.

Governance-led AI deployment

The rollout has been structured around enterprise governance principles. Access is managed through role-based access controls, single sign-on authentication and automated provisioning, ensuring that AI tools and information remain aligned to defined job responsibilities and permission boundaries.

ChatGPT Edu operates within a centrally managed internal workspace governed by consistent policies across the Group. External sharing and third-party integrations are enabled only where explicitly approved and aligned with business requirements, reinforcing a secure and compliant AI environment.

This governance-first approach reflects a deliberate shift from isolated experimentation to structured, scalable adoption.

From classroom innovation to enterprise infrastructure

EtonHouse previously developed Lumina, its proprietary AI-powered lesson planning platform. The deployment of ChatGPT Edu represents the next phase of integration, extending advanced artificial intelligence capabilities into enterprise functions.

Within the secure workspace, teams can upload documents for structured analysis, generate comparative reports, conduct scenario modelling and retrieve institutional knowledge more efficiently. Technology teams are also leveraging Codex, OpenAI’s agentic coding tool, to enhance development workflows, supporting code drafting, review and testing while maintaining human oversight and established engineering standards.

The Group is concurrently developing internal AI assistants and structured workflows within defined governance parameters to streamline routine processes and standardise how knowledge is accessed and applied across departments.

Augmentation, not replacement

EtonHouse emphasises that artificial intelligence is being implemented as an augmentation layer rather than a substitute for professional judgement.

“Artificial intelligence is not a shortcut or a replacement technology. It is a learning infrastructure,” said Mr Ng Yi-Xian, Group CEO of EtonHouse International Education Group. “We are developing tools that help students learn more confidently, support teachers to plan and differentiate more effectively, and equip HQ teams to serve schools faster and with higher quality. AI should amplify good practice, not replace it, so we are building the governance and capability to deploy it responsibly at scale.”

The rollout will be supported by structured staff training alongside OpenAI experts clear usage guidelines and ongoing oversight to ensure transparency, responsible usage and alignment with internal policies and regulatory obligations.

“As Singapore advances its national AI ambitions, many institutions are working to bridge the gap between rapidly advancing AI technologies and their ability to deploy them effectively and responsibly. EtonHouse’s rollout of ChatGPT Edu shows how forward-thinking education organisations can translate AI into practical, trusted enterprise-wide systems that empower teams today, while building confidence for the long-term.” added Oliver Jay, Managing Director, International at OpenAI.

Education’s role in Singapore’s AI future

Budget 2026 outlined the formation of a National AI Council to guide coordinated deployment across priority sectors including advanced manufacturing, connectivity, finance and healthcare.

EtonHouse’s implementation reflects how education institutions can apply similar principles of governance, security and enterprise readiness, positioning schools not only as adopters of technology but as contributors to Singapore’s broader AI capability building.

With this move, EtonHouse signals a transition from exploratory AI usage to secure, scalable integration across its global network, reinforcing its commitment to innovation anchored in institutional discipline and responsible deployment.

Hashtag: #ArtificialIntelligence #EnterpriseAI #AIGovernance #AIDeployment #EdTech

https://www.etonhouse.edu.sg/
https://www.linkedin.com/company/etonhouse-international-education-group/
https://twitter.com/EtonHouseGroup
https://web.facebook.com/EtonHouseInternational/
https://www.instagram.com/etonhouseinternational/

The issuer is solely responsible for the content of this announcement.

About EtonHouse International Education Group

In 2015, the EtonHouse Community Fund (ECF) was established, dedicated to enhancing the lives of underserved children and youth through education.

The Eton Academy was launched in 2020, providing English, Maths, and Science academic programmes for Nursery 1 to Primary 6 in centres across the island. Building on this success, The Eton Academy expanded in 2025 with the introduction of Elevate After School Care, offering primary school children a holistic, well-rounded after-school experience that complements their academic development.

EtonHouse International Education Group remains unwavering in its commitment to shaping futures and making a meaningful impact on the world through education.

Here are five fashion picks from Malaysian homegrown brands to shop from on 25 Feb Jualan Awal Ramadan:

1. UMMA

Step into Raya with UMMA’s Kebarung Labuh Harum Mekar, designed for effortless celebrations with its airy, semi-sheer fabric and loose silhouette. A favourite of Malaysian singer Mimi Fly, the piece blends timeless tradition with a touch of modern grace, featuring delicate lace trims and available in soft green and light cream colours.

For a limited time, shoppers can purchase a Kebarung Labuh Harum Mekar together with the Baju Kebarung Labuh in the same order to snag a complimentary blending sponge as a special add-on, and score up to 15% off orders totalling RM80 or above, exclusively on Shopee.

2. Asikin Ahmad

Crafted with versatility in mind, the Linen Bayu Sulam Kurung by Asikin Ahmad serves more than one occasion. Made from breathable linen, it provides cooling comfort during long festive days, while its relaxed silhouette and straight-cut skirt add structure.

Designed for versatility beyond Raya, the set remains suitable across functions from festive celebrations to professional settings, and comes in six available colours at Shopee’s Feb 25 Jualan Awal Ramadan. Explore the design and unlock a 15% off store voucher with a minimum spend of RM130, available exclusively on the platform.

3. Theins

Steal the spotlight this Syawal with Theins’ best-selling Mahsuri Baju Kurung for a lasting impression. Composed of a modern flared top with subtle shoulder pads, the silhouette frames the wearer with structured poise, while the pleated skirt introduces fluid movement that naturally draws attention.

Designed for those who appreciate statement dressing with polish, the set naturally draws attention with its range of stunning colours. For just RM146, shoppers can get up to 15% off their orders and check out any item from Theins’ new Raya collection to receive a complimentarysampul duit raya packet, thoughtfully included to ease preparations for duit raya exchanges.

4. Pazze

Capture the spirit of togetherness with coordinated family portraits in matching sets from Pazze. The father-son Baju Melayu Modern Slim Fit from the Sedondon Series is intentionally designed with discreet wudhu-friendly zips along the sleeves and sides. This thoughtful feature allows for easy ablution without compromising appearance, enabling wearers to transition seamlessly from prayers to Raya festivities.

With more than 10 colours and a broad size range for adults and children, Pazze offers Malaysians a functional choice for family dressing, and prayer times throughout Raya. Shoppers can also tune in to daily livestreams to watch their live product demonstrations and unlock exclusive 30% off vouchers for livestream purchases.

5. HAYĀ Group

With festive expenses often adding up quickly, finding a Raya outfit that balances style and affordability can be a challenge. With the Satin Blouse Set from HAYĀ Group, Malaysians can celebrate Raya guilt-free. Offering savings of up to 30% off exclusively on Shopee, the set presents a budget-conscious option for those seeking style without overspending, making festive fashion both accessible and rewarding.

The classic Kedah-cut top pairs effortlessly with a long wrap skirt that secures neatly at the waist, creating a flattering yet refined silhouette. Crafted from soft foil fabric that feels comfortable, wrinkle-resistant, and easy to iron, the fit remains ideal for enjoying celebrations without straining the wallet.

Shopee’s Bazar Hebat Ramadan Sale on 25 February

From exclusive vouchers to livestream discounts and affordable deals on Malaysia’s favourite local fashion brands, shoppers can add to cart their favourite festive look, support local names, and indulge in Shopee Lagi Murah prices exclusively at the Feb 25 Jualan Awal Ramadan Sale. With practical perks like Free Shipping with No Minimum Spend, Malaysians can ensure their orders arrive in time for balik kampung journeys and open house visits. Step into Syawal feeling coordinated, comfortable, and Raya-ready, only at Shopee’s Bazar Hebat Ramadan Sale.

Hashtag: #Shopee #Ramadan #Sale

The issuer is solely responsible for the content of this announcement.

Shopee

Shopee is the leading e-commerce platform in Southeast Asia, Taiwan, and Brazil. Shopee promotes an inclusive and sustainable digital ecosystem by enabling businesses to digitalise and grow their online presence, helping more people access and benefit from digital services, and uplifting local communities.

Shopee offers an easy, secure, and engaging experience that is enjoyed by millions of people daily. Shopee is also a key contributor to the region’s digital economy with a firm commitment to helping homegrown brands and entrepreneurs succeed in e-commerce.

Shopee is part of Sea Limited (NYSE: SE), a leading global consumer internet company. Sea’s mission is to better the lives of consumers and small businesses with technology through its three core businesses: Shopee, Garena, and Monee.

• UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
• In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
• UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.

GUANGDONG, CHINA & BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 February 2026 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G).

UBT251 is being jointly developed by TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology) and Novo Nordisk under an agreement signed in March 2025. United Biotechnology is responsible for development in Chinese mainland, Hong Kong, Macau and Taiwan, while Novo Nordisk is responsible for development in the rest of the world.

The trial, conducted by United Biotechnology, investigated the safety and efficacy of once-weekly injectable 2 mg, 4 mg and 6 mg doses of UBT251 compared to placebo in Chinese people with overweight or obesity. From a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7% (-17.5 kg) compared to 2.0% (-1.6kg) in the placebo group after 24 weeks of treatment[i].

Moreover, all dose groups of UBT251 showed statistically significant improvements relative to placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure and lipids.

In the trial, UBT251 appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with incretin-based therapies.

“The success of the phase 2 clinical trial of UBT251 in China represents another significant milestone in TUL’s innovation-driven development,” said Mr Tsoi Hoi Shan, Chairman of TUL. “We will continue to focus on chronic diseases, including endocrine and metabolic disorders, accelerate the further development of UBT251, and strive to bring more high-quality treatment options to patients worldwide at the earliest opportunity.”

“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “We look forward to reporting data from a global trial with UBT251 conducted by Novo Nordisk next year.”

Novo Nordisk recently initiated a global phase 1b/2a trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of UBT251 for up to 28 weeks in around 330 people living with overweight or obesity. Topline data from that trial is expected in 2027. Novo Nordisk also expects to initiate a phase 2 trial with UBT251 in people with type 2 diabetes in the second half of 2026.

United Biotechnology will present detailed data from the Chinese phase 2 trial at a medical congress later this year. Based on the results of this trial, the company is planning to initiate a phase 3 trial in Chinese patients with overweight or obesity.

About the Chinese phase 2 trial

This randomized, double-blind, placebo-controlled trial enrolled a total of 205 Chinese patients with obesity (BMI ≥ 28.0 kg/m²) or overweight (24.0 kg/m² ≤ BMI < 28.0 kg/m²) with at least one weight-related comorbidity. The baseline mean body weight of the patients was 92.2 kg, with a baseline mean BMI of 33.1 kg/m².

Patients were randomly assigned to receive weekly subcutaneous injections of UBT251 in doses of 2 mg, 4 mg, 6 mg, or placebo for 24 weeks.

The primary endpoint of the trial was the percentage change in body weight from baseline after 24 weeks of treatment.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.

In March 2025, United Biotechnology entered an exclusive license agreement with Novo Nordisk A/S for UBT251. Under the agreement, Novo Nordisk obtained exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialise UBT251. United Biotechnology retained the rights for UBT251 in Chinese mainland, Hong Kong, Macau and Taiwan.

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

About TUL and United Biotechnology

Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine, finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit www.tul.com.cn.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

• UBT251 是一款 GLP-1/GIP /GCG三靶點受體激動劑（三激動劑），由聯邦生物與諾和諾德聯合開發
• 在一項針對中國超重或肥胖患者的安慰劑對照 II 期臨床研究中，用藥 24 周後受試者平均體重降幅高達 19.7%，具有統計學意義
• UBT251 的安全性和耐受性良好，與基於腸促胰素的療法一致

中國廣東和丹麥巴格斯韋德 – Media OutReach Newswire – 2026年2月24日 – 聯邦制藥國際控股有限公司（「聯邦制藥」）與Novo Nordisk A/S（「諾和諾德」）今日宣佈GLP-1/GIP/GCG三靶點受體激動劑（三激動劑）UBT251中國II期臨床研究的主要結果。

UBT251 由聯邦制藥之全資附屬公司——聯邦生物科技（珠海橫琴）有限公司（「聯邦生物」）與諾和諾德根據 2025 年 3 月簽署許可協議共同開發。聯邦生物負責中國內地（大陸）、香港特別行政區、澳門特別行政區和臺灣地區的開發，諾和諾德負責除上述外全球範圍內的開發。

本次臨床研究由聯邦生物開展，旨在研究中國超重或肥胖患者每週一次注射2 mg、4 mg和6 mg劑量的UBT251與安慰劑對照的安全性和有效性。患者基線平均體重為92.2 kg，治療24周後，UBT251治療組的平均體重降幅最高達19.7%（-17.5 kg），而安慰劑組僅為2.0%（-1.6 kg）¹。

此外，與安慰劑組相比，UBT251 所有劑量組在關鍵次要終點方面均顯示出統計學顯著改善，包括腰圍、血糖、血壓和血脂。

本次研究中，UBT251 顯示出良好的安全性和耐受性。最常見的不良事件為胃腸道反應，絕大多數為輕度至中度，且隨時間推移而減輕，這與基於腸促胰素的療法一致。

「UBT251中國II期臨床研究的成功，是聯邦制藥創新發展的又一重要里程碑。」聯邦制藥主席蔡海山先生表示，「我們將持續聚焦內分泌和代謝性疾病等慢性疾病治療領域，加速推進UBT251的後續開發，早日為全球患者提供更多優質治療選擇。」

「中國臨床研究取得的結果令我們倍感鼓舞，展現了UBT251的潛力及其差異化的臨床特徵、安全性和耐受性特徵，」諾和諾德執行副總裁、首席科學官兼研發負責人Martin Holst Lange表示，「我們期待明年公佈諾和諾德開展的UBT251全球研究數據。」

諾和諾德近期啟動了一項全球性Ib/IIa 期臨床研究，旨在研究不同劑量 UBT251 在約 330 名超重或肥胖患者中長達 28 周的安全性、耐受性、藥代動力學和藥效學。該研究的主要數據預計將於 2027 年公佈。諾和諾德還計劃於 2026 年下半年啟動一項針對 2 型糖尿病患者的UBT251的 II期臨床研究。

聯邦生物將於今年晚些時候在醫學大會期間公佈其中國II期臨床研究的詳細數據。基於該研究結果，聯邦制藥計劃啟動一項針對中國超重或肥胖患者的III期臨床研究。

關於中國II期臨床研究

這項隨機、雙盲、安慰劑對照研究共納入205名中國肥胖（BMI≥28.0 kg/m²）或超重（24.0 kg/m²≤BMI<28.0 kg/m²）且至少合併一種體重相關疾病的患者。患者基線平均體重為92.2 kg，基線平均BMI為33.1 kg/m²。

患者被隨機分配接受每週一次皮下注射 2 mg、4 mg、6 mg劑量的UBT251或安慰劑，療程為 24 周。

該研究的主要終點是治療 24 周後體重較基線的百分比變化。

關於UBT251

UBT251是一種長效合成肽類GLP-1（胰高血糖素樣肽-1）、GIP（葡萄糖依賴性促胰島素多肽）和GCG（胰高血糖素）三靶點受體激動劑。

2025年3月，聯邦生物與諾和諾德就UBT251達成獨家許可協議。根據該協議，諾和諾德獲得UBT251在全球範圍內（除中國內地（大陸）、香港特別行政區、澳門特別行政區和臺灣地區）的獨家開發、生產和商業化權利。聯邦生物保留UBT251在中國內地（大陸）、香港特別行政區、澳門特別行政區和臺灣地區的相關權利。

______________________________
¹ 根據試驗方案的療效估計值，不考慮劑量調整

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

關於聯邦制藥和聯邦生物

聯邦制藥（香港聯交所股票代碼：3933）創立於一九九零年，主要從事藥品的研發、生產及銷售，是中國領先的綜合性製藥企業之一。目前擁有七家生產基地，產品涵蓋醫藥中間體及原料藥、製劑產品、獸藥、藥用空心膠囊、醫療器械，銷售網絡覆蓋全球近80個國家和地區。聯邦生物位於橫琴粵澳深度合作區，是聯邦制藥的生物醫藥研發總部，主要研發治療重大慢性疾病的高端生物藥物。更多資訊，請訪問www.tul.com.cn。

關於諾和諾德

諾和諾德是一家全球領先的醫療健康公司，成立於1923年，總部位於丹麥。我們的使命是基於在糖尿病領域的深厚積澱，推動變革以戰勝嚴重慢性疾病。我們通過開創科學突破、擴大藥物可及性以及致力於預防並最終治癒疾病來實現這一目標。諾和諾德在80個國家擁有約68,800名員工，產品銷往約170個國家。更多資訊，請訪問novonordisk.com,Facebook, Instagram, X, LinkedIn和YouTube。

• UBT251 是一款 GLP-1/GIP /GCG三靶点受体激动剂（三激动剂），由联邦生物与诺和诺德联合开发
• 在一项针对中国超重或肥胖患者的安慰剂对照 II 期临床研究中，用药 24 周后受试者平均体重降幅高达 19.7%，具有统计学意义
• UBT251 的安全性和耐受性良好，与基于肠促胰素的疗法一致

中国广东和丹麦巴格斯韦德 – Media OutReach Newswire – 2026年2月24日 – 联邦制药国际控股有限公司（「联邦制药」）与Novo Nordisk A/S（「诺和诺德」）今日宣布GLP-1/GIP/GCG三靶点受体激动剂（三激动剂）UBT251中国II期临床研究的主要结果。

UBT251 由联邦制药之全资附属公司——联邦生物科技（珠海横琴）有限公司（「联邦生物」）与诺和诺德根据 2025 年 3 月签署许可协议共同开发。联邦生物负责中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区的开发，诺和诺德负责除上述外全球范围内的开发。

本次临床研究由联邦生物开展，旨在研究中国超重或肥胖患者每周一次注射2 mg、4 mg和6 mg剂量的UBT251与安慰剂对照的安全性和有效性。患者基线平均体重为92.2 kg，治疗24周后，UBT251治疗组的平均体重降幅最高达19.7%（-17.5 kg），而安慰剂组仅为2.0%（-1.6 kg）¹。

此外，与安慰剂组相比，UBT251 所有剂量组在关键次要终点方面均显示出统计学显著改善，包括腰围、血糖、血压和血脂。

本次研究中，UBT251 显示出良好的安全性和耐受性。最常见的不良事件为胃肠道反应，绝大多数为轻度至中度，且随时间推移而减轻，这与基于肠促胰素的疗法一致。

「UBT251中国II期临床研究的成功，是联邦制药创新发展的又一重要里程碑。」联邦制药主席蔡海山先生表示，「我们将持续聚焦内分泌和代谢性疾病等慢性疾病治疗领域，加速推进UBT251的后续开发，早日为全球患者提供更多优质治疗选择。」

「中国临床研究取得的结果令我们倍感鼓舞，展现了UBT251的潜力及其差异化的临床特征、安全性和耐受性特征，」诺和诺德执行副总裁、首席科学官兼研发负责人Martin Holst Lange表示，「我们期待明年公布诺和诺德开展的UBT251全球研究数据。」

诺和诺德近期启动了一项全球性Ib/IIa 期临床研究，旨在研究不同剂量 UBT251 在约 330 名超重或肥胖患者中长达 28 周的安全性、耐受性、药代动力学和药效学。该研究的主要数据预计将于 2027 年公布。诺和诺德还计划于 2026 年下半年启动一项针对 2 型糖尿病患者的UBT251的 II期临床研究。

联邦生物将于今年晚些时候在医学大会期间公布其中国II期临床研究的详细数据。基于该研究结果，联邦制药计划启动一项针对中国超重或肥胖患者的III期临床研究。

关于中国II期临床研究

这项随机、双盲、安慰剂对照研究共纳入205名中国肥胖（BMI≥28.0 kg/m²）或超重（24.0 kg/m²≤BMI<28.0 kg/m²）且至少合并一种体重相关疾病的患者。患者基线平均体重为92.2 kg，基线平均BMI为33.1 kg/m²。

患者被随机分配接受每周一次皮下注射2 mg、4 mg、6 mg剂量的 UBT251或安慰剂，疗程为 24 周。

该研究的主要终点是治疗 24 周后体重较基线的百分比变化。

关于UBT251

UBT251是一种长效合成肽类GLP-1（胰高血糖素样肽-1）、GIP（葡萄糖依赖性促胰岛素多肽）和GCG（胰高血糖素）三靶点受体激动剂。

2025年3月，联邦生物与诺和诺德就UBT251达成独家许可协议。根据该协议，诺和诺德获得UBT251在全球范围内（除中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区）的独家开发、生产和商业化权利。联邦生物保留UBT251在中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区的相关权利。

______________________________
¹ 根据试验方案的疗效估计值，不考虑剂量调整

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

关于联邦制药和联邦生物

联邦制药（香港联交所股票代码：3933）创立于一九九零年，主要从事药品的研发、生产及销售，是中国领先的综合性制药企业之一。目前拥有七家生产基地，产品涵盖医药中间体及原料药、制剂产品、兽药、药用空心胶囊、医疗器械，销售网络覆盖全球近80个国家和地区。联邦生物位于横琴粤澳深度合作区，是联邦制药的生物医药研发总部，主要研发治疗重大慢性疾病的高端生物药物。更多信息，请访问www.tul.com.cn。

关于诺和诺德

诺和诺德是一家全球领先的医疗健康公司，成立于1923年，总部位于丹麦。我们的使命是基于在糖尿病领域的深厚积淀，推动变革以战胜严重慢性疾病。我们通过开创科学突破、扩大药物可及性以及致力于预防并最终治愈疾病来实现这一目标。诺和诺德在80个国家拥有约68,800名员工，产品销往约170个国家。更多信息，请访问novonordisk.com,Facebook, Instagram, X, LinkedIn和YouTube。